These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1131393)

  • 1. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.
    Struck RF; Kirk MC; Witt MH; Laster WR
    Biomed Mass Spectrom; 1975 Feb; 2(1):46-52. PubMed ID: 1131393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
    Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M
    Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry.
    Momerency G; Van Cauwenberghe K; Slee PH; Van Oosterom AT; De Bruijn EA
    Biol Mass Spectrom; 1994 Mar; 23(3):149-58. PubMed ID: 8148406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration.
    Struck RF; Alberts DS
    Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites.
    Jardine I; Brundrett R; Colvin M; Fenselau C
    Cancer Treat Rep; 1976 Apr; 60(4):403-8. PubMed ID: 1277214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Half-life of oxazaphosphorines in biological fluids.
    Sladek NE; Powers JF; Grage GM
    Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
    Low JE; Borch RF; Sladek NE
    Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alkylating properties of phosphoramide mustard.
    Colvin M; Brundrett RB; Kan MN; Jardine I; Fenselau C
    Cancer Res; 1976 Mar; 36(3):1121-6. PubMed ID: 1253171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
    Voelcker G; Wagner T; Hohorst HJ
    Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of deuterium-labeled analogs of cyclophosphamide and its metabolites.
    Griggs LJ; Jarman M
    J Med Chem; 1975 Nov; 18(11):1102-6. PubMed ID: 1177255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of cimetidine on cyclophosphamide metabolism in rabbits.
    Anthony LB; Long QC; Struck RF; Hande KR
    Cancer Chemother Pharmacol; 1990; 27(2):125-30. PubMed ID: 2249327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of neutrophil chemotaxis by 4-hydroxycyclophosphamide.
    Gilbert DN; Starr P; Eubanks N
    Cancer Res; 1977 Feb; 37(2):456-9. PubMed ID: 832269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
    Hong PS; Srigritsanapol A; Chan KK
    Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and identification of a stabilized derivative of aldophosphamide, a major metabolite of cyclophosphamide.
    Struck RF
    Cancer Res; 1974 Nov; 34(11):2933-5. PubMed ID: 4417999
    [No Abstract]   [Full Text] [Related]  

  • 15. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
    Hemminki K
    Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans.
    Fenselau C; Kan MN; Rao SS; Myles A; Friedman OM; Colvin M
    Cancer Res; 1977 Aug; 37(8 Pt 1):2538-43. PubMed ID: 872080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
    Friedman OM; Wodinsky I; Myles A
    Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients.
    Hadidi AH; Coulter CE; Idle JR
    Cancer Res; 1988 Sep; 48(18):5167-71. PubMed ID: 3409242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and quantitation of alcophosphamide, a metabolite of cyclophosphamide, in the rat using chemical ionization mass spectrometry.
    Hong PS; Chan KK
    Biomed Environ Mass Spectrom; 1987 Apr; 14(4):167-72. PubMed ID: 2954602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide.
    Boddy AV; Furtun Y; Sardas S; Sardas O; Idle JR
    J Natl Cancer Inst; 1992 Nov; 84(22):1744-8. PubMed ID: 1433359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.